A Phase II Study of Triapine in Combination With Gemcitabine in Recurrent/Unresectable/Metastatic Pancreatic Carcinoma

Trial Profile

A Phase II Study of Triapine in Combination With Gemcitabine in Recurrent/Unresectable/Metastatic Pancreatic Carcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Nov 2017

At a glance

  • Drugs OCX 191 (Primary) ; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Jun 2016 Time frame of the primary end point is changed from every 8 weeks to Every 8 weeks for the duration of the trial, an expected average of 5 years.
    • 22 Jul 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov.
    • 17 Aug 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top